A positive MTHFR mutation result usually changes nothing about your care. The two common variants, C677T and A1298C, are carried by a large share of healthy people, and no major guideline recommends testing for them or dosing folate by genotype. Your homocysteine level, not your genotype, decides what happens next.

TL;DR: Key takeaways

  • A positive result is common, and on its own it is not a diagnosis.
  • No guideline body recommends testing for this variant or adjusting folate by genotype.
  • The number that matters is homocysteine, read against your own laboratory's reference range.
  • Keep standard folic acid if pregnancy is possible. Do not swap it for methylfolate because of a gene result.
  • Get the symptom that worried you properly worked up: ferritin, B12, thyroid, and mood screening.

The honest answer: an MTHFR result usually does not change your care

An MTHFR variant is a common difference in the gene that makes an enzyme your body uses to produce 5-methyltetrahydrofolate, the folate form that converts homocysteine into methionine. The two frequently reported versions are polymorphisms, not rare disease-causing mutations. For most people they require no special treatment, no additional testing, and no change to how much folate they take.

The CDC is explicit. There are currently no clinical recommendations to test for MTHFR status, or to consume a different amount of folate or folic acid, based on genotype. That is not a cautious hedge. It is a statement that the result has no established clinical use.

The prevalence explains why. The C677T variant occurs in both gene copies in about 25% of Hispanic people and 10 to 15% of white North Americans, which makes it a common polymorphism rather than a rare finding.

The clotting story is what made this test popular, and it did not survive scrutiny. A meta-analysis of more than 11,000 venous thromboembolism cases found no evidence that C677T raises risk, and the American College of Medical Genetics and Genomics does not support routine clinical testing for it. If this line appeared on a panel of genetic testing you ordered out of curiosity, read it as information, not as a verdict.

MTHFR symptoms: the list you found online belongs to a different, rarer disease

The MTHFR symptoms you have read about, fatigue, brain fog, anxiety, low mood and recurrent miscarriage, have no established causal link to the C677T or A1298C variants. Most carriers have normal folate and homocysteine and no symptoms at all.

The alarming lists describe something else entirely. At least 40 separate, rare and severe mutations in this same gene cause homocystinuria, with eye problems, abnormal clotting, skeletal abnormalities and learning problems. That condition is usually identified in infancy or childhood, not discovered by an adult reading a consumer DNA report.

Your symptoms are real. The genotype simply does not narrow them down. Fatigue and brain fog run through iron deficiency, B12 deficiency, thyroid disease, poor sleep and depression. Low mood and persistent worry point toward major depression or generalized anxiety disorder. Recurrent miscarriage has its own obstetric evaluation. Get the symptom worked up rather than the gene: ferritin, B12, thyroid function, and a depression and anxiety screen.

If an ongoing complaint is what brought you here, August's $39 online urgent care visit is a reasonable place to start, where a US-licensed clinician decides whether testing or treatment is appropriate and prescribes only when it is. The visit cannot order or interpret genetic testing, so it is not a route to a gene panel.

Your homocysteine level, not your genotype, is the number that triggers action

Homocysteine levels are the only part of this picture that should change what you do. MedlinePlus states that genotype testing is appropriate only after an elevated homocysteine result plus other risk factors, never as a standalone screen, which means most people holding a report have done this in reverse order.

If your homocysteine is normal, the variant by itself should not change your supplements, your prescriptions, or your pregnancy plan. Not one of them.

A primary care clinician can order the follow-up: total homocysteine, fasting or not, with serum or red cell folate and vitamin B12. A hematologist is for clotting questions, an OB-GYN for pregnancy questions, and a certified genetic counselor, findable through the National Society of Genetic Counselors "Find a Genetic Counselor" directory, for a report you cannot make sense of.

Here is what most pages will not tell you: there is no single agreed figure that makes homocysteine "high". Adult reference ranges differ by laboratory, assay, age and B12 status, so read the range printed beside your own result and treat a flagged value as a reason for a conversation rather than a diagnosis.

If you change your diet or supplements, allow roughly 8 to 12 weeks before rechecking homocysteine levels and folate. That is a practical interval based on how slowly red cell folate turns over, not a guideline requirement. Spend the same visit on what genuinely moves risk: weight, smoking, physical activity, diabetes and blood pressure all outweigh the genotype.

MTHFR C677T, homozygous, or compound heterozygous: reading your report without panicking

MTHFR C677T is one of the two most frequently reported variants, alongside A1298C, and plenty of labs print the line as "MTHFR mutation detected", which is why readers arrive frightened. Find the genotype instead, written as C/T, T/T or A/C. The word "positive" is applied inconsistently between labs and tells you very little.

  • Heterozygous C677T (C/T), one copy: enzyme activity is near normal. Nothing to do beyond standard folate intake.
  • Homozygous C677T (T/T), two copies: the only group with a meaningful chance of mildly raised homocysteine. Check the level once.
  • MTHFR A1298C, one or two copies: less associated with raised homocysteine. Same standard care.
  • Compound heterozygous, one C677T plus one A1298C: treat it like homozygous C677T and check homocysteine once.

Notice that all four paths converge on nearly the same place. No genotype category earns a thrombophilia workup, anticoagulation or high-dose supplementation on its own, and patients who test positive need no special management on that basis alone.

Methylfolate versus folic acid: the swap most carriers do not need

Methylfolate, sold as L-5-MTHF, is the change almost every carrier is told to make, and the evidence does not support making it by default. The CDC's position is that all women capable of becoming pregnant should get 400 mcg of folic acid daily regardless of genotype, because the standard dose raises blood folate whatever the genotype, even though some genotypes carry roughly 16% lower baseline blood folate.

So do not stop or cut a prenatal folic acid dose in order to switch. Neural tube defect prevention rests on folic acid specifically, and trading a proven intervention for a fashionable one is a poor bargain during pregnancy.

If you do take it, know what you are buying. Over the counter, methylfolate comes in microgram amounts broadly comparable to a standard folate tablet, while prescription L-methylfolate is sold in milligram strengths many times higher, intended for specific medical indications rather than for a carrier with a normal homocysteine level. Strengths vary by brand, so read the panel. On a Supplement Facts label, look for "folate" followed by "as L-5-methyltetrahydrofolate", "L-methylfolate calcium", Metafolin or Quatrefolic. "Folic acid" means the synthetic form, which is also what fortified cereals, grains and enriched flour in the United States contain.

Food is the better opening move for anyone without a raised level. Leafy greens, lentils and other legumes, avocado, citrus, asparagus, eggs, nuts and liver all carry folate, and food folate needs no genotype asterisk. The rule worth memorising: a raised homocysteine level, not your genotype, is what justifies changing the form or dose of folate, and that change belongs in a conversation with a clinician.

When MTHFR is the wrong explanation: symptoms that need care today

The real harm in this topic is a reader filing an urgent problem under a benign gene result. Sort by the symptom.

Call 911 or go to an emergency room now if:

  • You have sudden shortness of breath, chest pain, or you are coughing up blood. These can signal a pulmonary embolism.

Book a visit within the next week if:

  • One leg becomes swollen, warm, red or painful. A possible deep vein thrombosis needs urgent in-person assessment, not attribution to your gene result.
  • An infant or young child has failure to thrive, developmental delay, seizures, or an unexplained dislocated eye lens. That warrants prompt pediatric evaluation for homocystinuria.

Talk to a clinician before you start if:

  • You are about to begin high-dose methylfolate or B12.
  • You want to change a prenatal vitamin.
  • You take methotrexate or another antifolate medication.
  • You or a close relative has had a venous thromboembolism.
  • You are planning a pregnancy.

If you are unsure which of those three tiers you are in, the free August AI Symptom Checker can help you triage where to take the symptom next. It does not diagnose anything, and it is no substitute for in-person care when something is acute.

The bottom line: your three-step MTHFR plan

First, do not act on the genotype alone. If you want data, get one total homocysteine level with folate and B12. Second, if it is normal, keep your folate intake standard, including 400 mcg of folic acid daily if pregnancy is possible. Third, if it is raised, take the result to a clinician, address the modifiable risk factors, and recheck in about 8 to 12 weeks. On its own, this variant needs no special management.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment decisions. If you are experiencing a medical emergency, call 911 or go to the nearest emergency room immediately.

Frequently Asked Questions

Not usually. Self-pay pricing at direct-to-consumer labs runs around $198. Insurers commonly deny the claim as not medically indicated, and the reasoning is circular but consistent: because no body recommends screening for this variant, there is rarely a diagnosis code that justifies paying for it. Coverage is more likely when a clinician is investigating an abnormal blood result with other risk factors present.

No. It is generally less associated with raised homocysteine than C677T, and nothing about it calls for different care. It sounds more ominous online mainly because it has been studied less, which leaves more room for speculation on wellness sites. Less published data is not the same thing as more danger.

Not usually. No guideline recommends testing in either situation, and the result would not change your prenatal care. Recurrent pregnancy loss deserves a dedicated evaluation directed by an OB-GYN, who can look for causes that actually alter treatment. Spending the visit on that workup is a far better use of your appointment than a genotype.

Sometimes. Consumer arrays are reasonably accurate for common single-letter variants like these, but raw data files are not clinical results, are not confirmed in a diagnostic laboratory, and are often filtered through third-party interpretation sites with no medical oversight. If a real decision depended on the answer, you would confirm it properly. For this gene, no decision should.

No, not on the strength of the genotype. L-methylfolate is prescribed in some cases as an adjunct in depression treatment, and methotrexate is an antifolate, so folate supplementation alongside it follows specific prescribing rules about dose and timing. Both of those are decisions for the clinician who writes the prescription, not purchases to make in a supplement aisle.

No. Testing relatives for a finding that does not change management in the person who already has it mostly spreads the worry. Standard folate advice applies to them whatever their genotype. Cascade testing earns its place for variants that change treatment, screening or reproductive decisions, and this is not one of those.